Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia

Retrieved on: 2022-07-14 19:14:06

Tags for this article:

Click the tags to see associated articles and topics

Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia. View article details on hiswai:

Excerpt

NORTHBROOK, IL, USA I July 13, 2022 I Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy ...

Article found on: pipelinereview.com